NMNiayesh Mohebbi

Niayesh Mohebbi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Niayesh Mohebbi has a total of 71 co-authors. Here are the top co-authors by number of shared publications:

  • Fatemeh Mohammadian

    Department of Psychiatry, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran

    3 shared publications
  • Amir Rezazadeh

    Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Fatemeh Mohammadian

    Department of Psychiatry, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Homayoun Amini

    Department of Psychiatry, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Kheirollah Gholami

    Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Mahsa Panahishokouh

    Department of Clinical Pharmacy, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran

    2 shared publications

Latest Publications

  • Open Access

    Biocompatible nanoscale contrast agents for MRI and CT scans: current progress and clinical potential

    by Mohammad Mehdi Gravandi, Pershia Davoodi Karsalari, Ali Hajihashemi, Shokouh Sadeghizadeh, Mohammad Rasoul Golabchi, Ghazal Mohammadbeigi, Mahsa Geravandi, Niayesh Mohebbi

    Conventional contrast agents for magnetic resonance imaging (MRI) and computed tomography (CT) have long served as the backbone of diagnostic imaging. Yet, their well-recognized limitations, including nephrogenic systemic fibrosis and progressive gadolinium deposition with Gd-based chelates, contrast-induced nephropathy with iodinated agents, and serious hypersensitivity reactions with approved iron oxide formulations, continue to drive the search for safer alternatives. Nanoparticle-based contrast agents (NCAs) have emerged as a compelling next generation of imaging tools, offering a degree of rational design simply not achievable with small-molecule agents. By independently tuning core composition, hydrodynamic size, surface chemistry, and morphology, NCAs can be engineered to enhance relaxivity or X-ray attenuation, extend vascular residence time, direct clearance toward renal or hepatobiliary pathways, and carry targeting ligands for site-specific delivery. This review covers the principal NCA classes, iron oxide nanoparticles, gadolinium- and manganese-based nanomaterials, gold and copper nanostructures, carbon dots, lanthanide-doped upconversion nanocrystals, and quantum dots, examining their physicochemical design, pharmacokinetics, biocompatibility, and diagnostic performance across oncological and vascular applications. A recurring theme is the central role of size: Particles below the ≈6 nm glomerular filtration threshold undergo renal excretion and exhibit lower bioaccumulation risk, while larger formulations follow hepatobiliary routes with implications for long-term tissue retention. Surface coating, protein corona formation, and mononuclear phagocyte system recognition are discussed as equally decisive determinants of in vivo behavior, often outweighing core composition in their influence on clearance and tolerability. Across material classes, preclinical evidence consistently shows favorable safety profiles for well-engineered NCAs, with minimal hemolysis, low immunogenicity, and absence of histological organ injury at imaging-relevant doses, a meaningful contrast to the adverse effect profiles of conventional agents. On the efficacy side, targeted NCA formulations have demonstrated promising results across multiple tumor types, including breast, brain, liver, lung, and renal cancers, with receptor-specific designs enabling molecular-level lesion characterization that conventional agents cannot provide. Multimodal and theranostic constructs, combining MRI or CT contrast with concurrent therapeutic function, further illustrate the flexibility that nanoparticulate platforms offer. Blood–brain barrier penetration for neurooncological applications and the emerging potential of magnetic particle imaging as a future translational direction for platforms based on superparamagnetic iron oxide nanoparticles are also discussed. The translational gap between preclinical promise and clinical reality remains the field’s most honest challenge, rooted in the scarcity of long-term human safety data, the lack of standardized preclinical evaluation frameworks, and the demanding requirements of good-manufacturing-practice production at scale. Addressing these gaps, through unified safety pipelines, harmonized reporting standards, and early-phase trials that connect imaging performance to clinical outcomes, is what will ultimately determine whether NCAs fulfill their considerable potential in diagnostic medicine.

  • Assessment of the Efficacy of Quercetin in Adult Patients With Autism Spectrum Disorder: A Randomized, Triple‐Blind, Placebo‐Controlled Trial

    by Anahid Rezaeifar, Mahtab Motamed, Niayesh Mohebbi

    Objectives: This randomized, triple‐blind, placebo‐controlled clinical trial evaluated the efficacy and safety of quercetin in adults with autism spectrum disorder (ASD). Methods: Fifty‐two adults with ASD were randomly assigned to receive either quercetin or placebo for 60 days. Outcomes included the Social Responsiveness Scale (SRS), WHO Quality of Life (WHOQOL) domains, and other clinical measures assessed at baseline, 30 days, and 60 days. Results: Baseline demographic characteristics and comorbid conditions were comparable between groups. The quercetin group showed a significant within‐group reduction in SRS scores over time ( p = 0.010), whereas the placebo group showed no significant change ( p = 0.655). However, between‐group differences in SRS change were not statistically significant. At week 8, the physical health domain of WHOQOL improved more in the quercetin group at the unadjusted level ( p = 0.044), but this was not significant after adjustment ( p = 0.082). The environmental health domain showed a borderline difference favoring quercetin (adjusted p = 0.053). Conclusion: Quercetin supplementation showed potential benefits in select social quality of life and social domain responsiveness in participants with ASD. Larger, well‐designed trials are needed to confirm its clinical effectiveness. Trial Registration: IRCT20241214064050N1


  • Medication discrepancies and medication-related problems in psychiatric patients: A medication reconciliation study

    by Mozhdeh Shahabi, Mahsa Panahishokouh, Niayesh Mohebbi

    Medication discrepancies (MDs) are common medication errors that can lead to adverse drug events (ADEs) and suboptimal treatment. Medication reconciliation (MR) programs are implemented in many countries, including Iran, to identify, resolve, and prevent MDs and other medication-related problems (MRPs). In the psychiatric setting, the importance of identifying and addressing MRPs is even greater due to the high prevalence of polypharmacy, limited patient cooperation, and other factors. This study aimed to comprehensively investigate the prevalence of MDs and MRPs in psychiatric patients. This study included 302 psychiatric patients receiving at least two systemic medications daily. Their medications were reviewed at discharge using the Pharmaceutical Society of Australia (PSA) guidelines to identify MRPs. The collected data were analyzed statistically. In this study, patients were taking a total of 1421 medications (4.71 medications per patient). A total of 493 MDs and 392 MRPs were identified. The most common MRPs were, in decreasing order, medication underuse or non-adherence by the patient (175 cases, 44.64% of all MRPs) and drug interactions (168 cases, 42.85%). The number of drug interactions significantly increased with the increasing number of underlying diseases and the number of medications used (P < 0.001 in both cases). The findings of this study indicate a high prevalence of medication-related problems (MRPs) in psychiatric settings, highlighting the critical role of MR programs in mitigating such risks. Among the challenges identified, non-adherence to treatment and potential drug interactions emerged as the most significant issues affecting psychiatric patients.

  • Open Access

    The Effects of Vitamin D Supplementation on Vertigo and Tinnitus in Patients with Meniere’s Disease: A Randomized Clinical Trial

    by Ali Talebi, Nasrin Yazdani, Amir Kasaeian, Sepide Talebi, Niayesh Mohebbi

    Background: The present study aimed to evaluate the impact of vitamin D supplementation as an adjuvant therapy on tinnitus and vertigo in individuals diagnosed with Meniere’s disease. Methods: The study was conducted from November 2021 to October 2022 at Tehran University Hospital, Tehran, Iran. This clinical trial involved 60 individuals diagnosed with Meniere’s disease and vitamin D deficiency. Participants were randomly allocated to receive either vitamin D (50,000 IU weekly) or a placebo for eight weeks. The study assessed the frequency, intensity, and duration of vertigo attacks, as well as several measures of dizziness and tinnitus, both before and after the intervention. Results: No significant change was observed in the number of vertigo attacks (P = 0.85), the duration (P = 0.52), or the severity of vertigo (P = 0.33) in the vitamin D group compared to the placebo group at the end of the trial. Additionally, vitamin D supplementation did not significantly affect the results of various dizziness and tinnitus indices at the study’s conclusion (P > 0.05). As expected, serum levels of vitamin D were significantly higher in the intervention group compared to the placebo group at the trial's endpoint (P < 0.001). Conclusions: Vitamin D supplementation did not significantly affect vertigo and tinnitus in patients with Meniere’s disease. Further clinical trials with larger sample sizes and longer durations are recommended to confirm these findings.


  • Open Access

    Investigating the Creation of a Ketogenic State With the Designed 4:1 Keto Classic Formulation in Patients With Traumatic Brain Injury

    by Shirin Shayanfar, Naficeh Sadeghi, Mannan Hajimahmoodi, Morteza Faghih Jouibari, Mohammad Rostami Ravari, Niayesh Mohebbi

    The beneficial effects of the ketogenic diet (KD) have been well demonstrated in children with convulsive disorders and epilepsy. Its potential therapeutic impact, primarily through limiting glucose availability to the brain, is currently being investigated in other neurological conditions such as Alzheimer′s and Parkinson′s diseases. Given the neuroprotective properties attributed to this dietary approach, the present study aimed to evaluate its effects in patients with traumatic brain injury (TBI). This randomized, double‐blind clinical trial enrolled 20 adult patients with TBI admitted to the intensive care unit (ICU). Participants were randomly assigned to either the intervention or control group according to the inclusion criteria. The primary outcome was the induction of ketosis using the formulated KD. Secondary outcomes included mortality rate, duration of mechanical ventilation, and changes in the Glasgow Coma Scale (GCS). All patients in the intervention group who received the designed ketogenic formulation showed positive urinary ketone tests, confirming ketosis induction. There were no significant differences between groups in mortality rate or duration of mechanical ventilation. However, a significant improvement in GCS was observed within the intervention group between the first and last study days, although intergroup comparison showed no significant difference. The ketogenic diet may contribute to improved neurological recovery, as reflected by GCS impron some patients with TBI. Nevertheless, larger‐scale studies are warranted to confirm its efficacy and safety in this population. Clinical Trial Registration: This study was registered in the International Clinical Trials Registry Platform (IRCT) under registration code 20230517058215N1.

  • Open Access

    A randomized, double-blind, placebo-controlled clinical trial to evaluate pregabalin efficacy in the treatment of behavioral and psychological symptoms of dementia in patients with Alzheimer’s disease

    by Leyla Maleki, Fatemeh Mohammadian, Mahsa Panahishokouh, Niayesh Mohebbi

    Background: Behavioral and Psychological Symptoms of Dementia (BPSD) are common during Alzheimer’s disease and cause severe problems for patients and their caregivers.Objectives: To assess the therapeutic efficacy of Pregabalin in comparison with a placebo in treating BPSD in patients with Alzheimer’s disease (AD) visiting the memory and cognition clinic of Roozbeh Psychiatric Hospital in Tehran, Iran.Methods: A 12-week double-blind, randomized comparison of Pregabalin and placebo treatments was conducted in 53 patients with DSM-V diagnosis of dementia of Alzheimer’s type. They were randomly assigned to receive Pregabalin (doses: 50 titrated up to 300 mg/day) or a placebo. Clinical response was evaluated using the Neuropsychiatric Inventory (NPI), and the Behavioral Pathology in AD Rating Scale (BEHAVE-AD) scores compared with baseline. Side effects were also recorded carefully.Results: Patients receiving Pregabalin had better outcomes in comparison with patients receiving a placebo regarding both NPI and BEHAVE-AD scores after 12 weeks (p-value = 0.009 for NPI and p-value = 0.003 for BEHAVE-AD). There was also a statistically significant decrease in the treatment group depression sub-score regarding NPI and BEHAVE-AD (respectively, p-value =0.000, 0.003). The caregiver burden sub-score of the NPI test was also lower in patients receiving pregabalin (p-value = 0.000). There was no statistically significant difference between the occurrence of adverse effects between the two groups (p-value = 1.00).Conclusion: Pregabalin at a dose of 300 mg/day was well tolerated and associated with reductions in the severity and frequency of behavioral symptoms in patients with AD. Pregabalin could be considered a favorable choice for treating BPSD in adults with mild to moderate stages of Alzheimer ‘s-type dementia, considering its befitting safety profile.Clinical trial registration: https://www.irct.ir/trial/52750, identifier IRCT20201201049553N1


  • Open Access

    The Efficacy and Safety of Fluoxetine Delayed-Release 90 mg/Weekly in Psychiatry: An Evidence-Based Mini-Review

    by Niayesh Mohebbi, Mahtab Motamed, Mahsa Panahishokouh

    Context: Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), is widely used in the treatment of various psychiatric disorders. While the standard therapeutic dose of fluoxetine is typically 20 - 60 mg per day, slow-release higher doses, such as 90 mg/weekly and more recently 180 mg/weekly, have been explored to assess their potential benefits in certain psychiatric conditions. This mini-review aims to evaluate the evidence regarding the effects, efficacy, and safety profile of fluoxetine at a dosage of 90 mg in psychiatry. Evidence Acquisition: A comprehensive literature search was conducted using electronic databases (PubMed and Embase) to identify relevant studies published until July 2023. Studies investigating the use of fluoxetine at a dosage of 90 mg/week in psychiatric conditions were included. The identified studies were critically appraised for their methodology and quality. Results: Limited research has specifically examined the effects of fluoxetine at a dosage of 90 mg/week in psychiatry. However, some studies have investigated this dosage form and provided insights into its potential efficacy in treating certain psychiatric conditions, such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), premature ejaculation, and premenstrual dysphoric disorder. These studies have shown that compliance with weekly fluoxetine was better than with once-daily dosing. Conclusions: Once-weekly dosing may be effective in psychiatry, improving compliance and enhancing psychological well-being.

  • Open Access

    Impact of Clinical Pharmacist-led Interventions on the Outcomes of Patients with Bipolar I Disorder: A Randomized Clinical Trial

    by Nazanin Gorgzadeh, Niayesh Mohebbi, Kheirollah Gholami, Homayoun Amini, Ali-Akbar Nejatisafa, Jamshid Salamzadeh

    Objective: Poor medication adherence, drug interactions, and adverse drug events occur frequently in patients with bipolar I disorder (BD-I), affecting their treatment outcomes. Due to limited research regarding the impact of pharmaceutical care (PC) services in the management of patients with BD-I, this study was designed to assess the role of clinical pharmacist-led interventions on outcomes of BD-I patients. Methods: A prospective randomized clinical trial was designed, and 59 patients were randomly assigned to the intervention group and 48 patients to the control group. Patients in the intervention group were provided with medication therapy management and follow-up services by the clinical pharmacist, whereas the control group only received routine care. Outcomes which were assessed at baseline (before discharge), 1 month, and 3 months after discharge were the Medication Appropriateness Index (MAI), Beck Depression Inventory-II (BDI-II), Young Mania Rating Scale, and World Health Organization Quality of Life, Brief version (WHOQOL-BREF). Findings: Endpoint mean changes in MAI scores from baseline were −5.25 ± 5.19 and 2.02 ± 3.98 points for the intervention and control groups, respectively (P < 0.001). Depressive symptoms, measured by the BDI-II, also showed significant improvement in the intervention group; the mean change from baseline to 2nd follow-up assessment was −1.47 ± 7.73 in the intervention group and 1.66 ± 6.42 in the control group (P = 0.02). Furthermore, the mean change from baseline to 2nd follow-up in the psychological health domain of the WHOQOL-BREF questionnaire was significantly higher in the intervention group (4.59 ± 17.79) compared with the control group (−3.90 ± 12.55) (P = 0.005). Conclusion: Our findings reveal that clinical pharmacist-provided services could positively affect outcomes in BD-I patients.


  • Open Access

    Adverse Drug Reactions of Multiple Sclerosis Disease-modifying Drugs

    by Maryam Salehbayat, Roya Abolfazli, Niayesh Mohebbi, Seyed Mehrdad Savar, Gloria Shalviri, Kheirollah Gholami

    Introduction: High frequency of adverse drug reactions (ADRs) challenges multiple sclerosis (MS) treatment. This study aims to assess the nature and frequency of ADRs induced by MS medications in an observational cross-sectional study. Methods: ADRs of all outpatients who had seen a neurologist and had received at least one disease-modifying therapy ...


  • Open Access

    Evaluating the Effects of Rivastigmine on Decision-Making in Patients with Mild Cognitive Impairment by Cambridge Neuropsychological Test Automated Battery (CANTAB); A Randomized, Double-Blind, Placebo-Controlled Trial

    by Setayesh Sadeghi, Fatemeh Mohammadian, Mehdi Tehrani-Doost, Kheirollah Gholami, Niayesh Mohebbi

    Background: Decision-making is a complex process, and most studies showed that patients with mild cognitive impairment (MCI) make worse decisions than healthy people. Objectives: This study aims to evaluate the effect of rivastigmine on the decision-making of MCI patients using the Cambridge Neuropsychological Test Automated Battery (CANTAB) tests. Methods: The study was conducted at the Roozbeh Hospital neurology clinic, and 30 patients with mild cognitive impairment over 40 years old were randomly recruited to receive rivastigmine or placebo twice daily for 12 weeks. The initial dose of rivastigmine or placebo was 1.5 mg twice daily and was increased to 3 mg twice daily per patient compliance. A CANTAB test was conducted before and following the intervention. Results: The mean age of patients in the rivastigmine group was 58.93 ± 10.88, and in the placebo group was 59.33 ± 10.34. The median MMSE (Mini-Mental State Examination) was 26 (IQR = 25 - 26) in both groups. Patients in the rivastigmine group showed significant differences in all subgroup tests of CGT, IST, and SST except in risk adjustment in the CGT test, discrimination in the IST test, and median correct RT on the go trial and SSRT in the SST test. The most commonly reported adverse effects were gastrointestinal complications. Conclusions: According to the results, rivastigmine significantly improved the primary decision-making outcomes in comparison with placebo.